Combined treatment of soft tissue and osteosarcomas by radiation and ICRF 159

Abstract

In a pilot clinical assessment of combined radiotherapy with the antimitotic agent ICRF 159, a good response was obtained in 18 of 22 patients (82%) with soft tissue and bone sarcomas. Six patients had complete regressions and 12 had regressions of 50% or more. Two had regressions of less than 50% and only 2 showed no response. Severe toxicity requiring interruption of treatment was not observed, but skin reactions were greater than expected. No lung reactions were seen. The combination appears to be synergistic.